Scpharmaceuticals Inc (SCPH) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Scpharmaceuticals Inc   (NASDAQ: SCPH)

Select the Financial Report: Select the Period:


Description of Scpharmaceuticals Inc's Business Segments


Scpharmaceuticals Inc operates primarily within the healthcare sector, and its business is divided into two major segments: BioPharmaceuticals and Medical Devices. Each segment encompasses a variety of innovative products and services designed to address multiple medical needs and improve patient care.

Segments

1. BioPharmaceuticals: This segment focuses on the development and commercialization of biopharmaceutical products that primarily aid in the treatment of serious health conditions. The company emphasizes the importance of delivering effective medications that enhance patient outcomes while ensuring ease of use and accessibility.

2. Medical Devices: Scpharmaceuticals Inc also specializes in medical devices that provide unique therapeutic solutions. This segment highlights the company’s commitment to integrating technology with healthcare to deliver advanced therapies in a user-friendly manner.

Products and Services

1. Furosemide Injection
- Description: A potent diuretic used to treat fluid retention due to conditions such as heart failure, liver disease, and kidney disorders.
- Formulation: Available in a pre-filled, single-use syringe, making it easier for healthcare providers to administer while minimizing waste and improving safety.
- Benefits: Streamlined administration offers potential for improved patient outcomes, particularly in acute settings.

CleveR Patch
- Description: An innovative medical device designed to provide an advanced form of Rehydration Therapy for acute dehydration.
- Mechanism: This wearable system enables rapid hydration through skin absorption, allowing it to effectively deliver electrolytes without the need for intravenous therapy.
- Applications: Suitable for both hospital and outpatient settings, particularly beneficial for patients unable to maintain hydration orally.

Subcutaneous Ceftriaxone
- Description: A broad-spectrum antibiotic effective against a variety of bacterial infections.
- Innovation: Scpharmaceuticals provides a unique formulation that allows for self-administration via subcutaneous injection, facilitating home treatment and reducing hospitalization rates.
- Target Audience: This product is particularly advantageous for patients with limited access to healthcare facilities or those who prefer home care options.

GammaCore
- Description: A non-invasive, portable device designed to alleviate symptoms associated with migraines and cluster headaches.
- Technology: It works by stimulating the vagus nerve, offering a novel alternative for patients who do not respond well to traditional migraine treatments or those who face side effects.
- Approval: FDA-approved, ensuring that it meets rigorous safety and efficacy standards.

VIBEX Epinephrine
- Description: An auto-injector device for the treatment of severe allergic reactions (anaphylaxis).
- Design: Compact and user-friendly, VIBEX is intended to be intuitive for patients to use in emergency situations, designed with affordability in mind.
- Significance: It helps bridge the gap for patients who may face challenges in accessing emergency care during critical allergic reactions.

Urgent PC
- Description: A medical device providing Percutaneous Tibial Nerve Stimulation (PTNS) therapy, which addresses bladder function issues in patients with overactive bladder symptoms.
- Non-invasive Nature: The treatment can be performed in an outpatient setting, significantly enhancing patient comfort and convenience.
- Outcome: Aimed at improving quality of life by alleviating uncomfortable bladder-related symptoms without invasive procedures.

Additional Services

Beyond its product offerings, Scpharmaceuticals Inc is dedicated to enhancing the patient experience through a robust suite of support services:
- Reimbursement Assistance: Helping patients navigate the complexities of insurance and payment options to ensure access to medications and devices.
- Medication Counseling: Providing patients and caregivers with comprehensive information about the proper use of prescribed products to optimize outcomes.
- Product Education: Offering resources and training to both patients and healthcare providers to ensure that products are utilized effectively.

Scpharmaceuticals Inc’s commitment to delivering innovative, patient-centric solutions is evident in its extensive range of products and supportive services, which aim to improve health outcomes and enhance the quality of life for patients across various healthcare settings.


Composition of Scpharmaceuticals Inc Revenues by Segments

 
Segment    100 % of total Revenue

Q2 three months ended (Jun 30 2025)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Segment 16.04 100 %
Total 16.04 100 %




Q2 three months ended (Jun 30 2025)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Segment 99.17 % -
Total 99.17 % 36.5 %




Q2 three months ended (Jun 30 2025)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -18.02 -




Q2 three months ended (Jun 30 2025)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Scpharmaceuticals Inc Divisions, Sales by Country

 
Segment   Segment Segment contribution to total sales 100 % of total Revenue


Twelve months ended 2024
SCPH s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Segment 36.33 100 %
Total 36.33 100 %


Twelve months ended 2024
SCPH s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -85.15 -

Twelve months ended 2024
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Segment 167.28 % -
Total 167.28 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.